William Blair & Company
LOGC

William Blair & Company’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

William Blair & Company’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,950
Closed -$51K – 2031
2021
Q4 		$51K Buy
+21,950
New +$74.3K ﹤0.01% 1778

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

William Blair & Company's LOGC Position: Q1 2022 in Review

William Blair & Company sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 21,950 shares — an estimated $51K sold.

William Blair & Company first reported a position in LOGC in Q4 2021 and held it in 1 quarter. The position peaked at $51K in Q4 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • William Blair & Company reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 21,950 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $51K.
  • William Blair & Company first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • William Blair & Company's LogicBio Therapeutics, Inc. Common Stock position peaked at $51K in Q4 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.